Author, as appears in the article.: Lopez-Sanchez, Alicia; Perez-Cantero, Alba; Torrado-Salmeron, Carlos; Martin-Vicente, Adela; Garcia-Herrero, Victor; Angeles Gonzalez-Nicolas, Maria; Lazaro, Alberto; Tejedor, Alberto; Torrado-Santiago, Santiago; Jose Garcia-Rodriguez, Juan; Capilla, Javier; Torrado, Susana
Department: Ciències Mèdiques Bàsiques
URV's Author/s: Capilla Luque, Javier / MARTÍN VICENTE, ADELA / PÉREZ CANTERO, ALBA
Keywords: Toxicity evaluation Therapy Pulmonary concentrations Pulmonary aspergillosis Nervous-system aspergillosis Nephrotoxicity Nanoparticles Murine model Mice Male Lung Lipid complex Kidney Immunosuppressed mice Fungal-infections Efficacy Drug combinations Deoxycholic acid Deoxycholate Comparative pharmacodynamics Aspergillosis Antifungal agents Antifungal Animals Amphotericin b, deoxycholate drug combination Amphotericin b
Abstract: An experimental micellar formulation of amphotericin B (AMB) with sodium deoxycholate (DCH), AMB:DCH 1:1.5, was obtained and characterized to determine its aggregation state and particle size. Biodistribution, nephrotoxicity and efficacy against pulmonary aspergillosis in a murine model were studied and compared to the liposomal commercial amphotericin B after intravenous administration. The administration of 5 mg/kg AMB:DCH 1:1.5 presented 2.8-fold higher lung concentrations (18.125 ± 3.985 μg/g, after 6 daily doses) and lower kidney exposure (0.391 ± 0.167 μg/g) compared to liposomal commercial amphotericin B (6.567 ± 1.536 and 5.374 ± 1.157 μg/g, in lungs and kidneys, respectively). The different biodistribution of AMB:DCH micelle systems compared to liposomal commercial amphotericin B was attributed to their different morphology and particle size. The efficacy study has shown that both drugs administered at 5 mg/kg produced similar survival percentages and reduction of fungal burden. A slightly lower nephrotoxicity, associated to amphotericin B, was observed with AMB:DCH 1:1.5 than the one induced by the liposomal commercial formulation. However, AMB:DCH 1:1.5 reached higher AMB concentrations in lungs that could represents a therapeutic advantage over liposomal commercial amphotericin B-based treatment of pulmonary aspergillosis. These results are encouraging to explore the AMB:DCH 1:1.5 usefulness against this disease.Copyright © 2018 American Society for Microbiology.
Thematic Areas: Saúde coletiva Química Pharmacology (medical) Pharmacology & pharmacy Pharmacology Odontología Nutrição Microbiology Medicina veterinaria Medicina iii Medicina ii Medicina i Materiais Matemática / probabilidade e estatística Interdisciplinar Infectious diseases Farmacia Ensino Engenharias iv Engenharias iii Engenharias ii Enfermagem Educação física Educação Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências agrárias i Ciência de alimentos Biotecnología Biodiversidade Astronomia / física
licence for use: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 00664804
Author's mail: javier.capilla@urv.cat
Author identifier: 0000-0002-0765-6403
Record's date: 2024-10-12
Papper version: info:eu-repo/semantics/acceptedVersion
Link to the original source: https://aac.asm.org/content/62/7/e00489-18
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Antimicrobial Agents And Chemotherapy. 62 (7): e00489-18-
APA: Lopez-Sanchez, Alicia; Perez-Cantero, Alba; Torrado-Salmeron, Carlos; Martin-Vicente, Adela; Garcia-Herrero, Victor; Angeles Gonzalez-Nicolas, Maria; (2018). Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis. Antimicrobial Agents And Chemotherapy, 62(7), e00489-18-. DOI: 10.1128/AAC.00489-18
Article's DOI: 10.1128/AAC.00489-18
Entity: Universitat Rovira i Virgili
Journal publication year: 2018
Publication Type: Journal Publications
Repositori URV